Published

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2026-01-01
Source: PubMed
DOI: 10.1177/02698811251362390
PubMed: 40883964

Authors

McGowan NM Rucker JJ Yehuda R Agrawal M Modlin NL Simmons H Tofil-Kaluza A Das S Goodwin GM

Watch author

Derived topics and classifications

psilocybin Depression PTSD Headache / Migraine Clinical Trial Treatment-Resistant Depression Healthcare Workers Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 8 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial2026-07-30 Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder2026-07-16 Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions2026-07-02 Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants2026-07-01 Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico2026-06-17 Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications2026-04-01 Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.2026-01-01

Related papers

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-07-21